Single-dose CpG immunization protects against a heterosubtypic challenge and generates antigen-specific memory T cells

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Vogel, Alexander J ^a,b   Brown, Deborah M ^a,b  

^a UNIVERSITY OF NEBRASKA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

CD4 T lymphocytes; CD8 T lymphocytes; CpG; Cytotoxic T lymphocytes; Immunization; Influenza A virus; Nasal mucosa; Vaccines

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

EID: 84935089355     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00327     Document Type: Article

References (50)

1. La Gruta NL, Turner SJ. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol (2014) 35:396-402. doi: 10.1016/j.it.2014.06.004.
2. Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science (2009) 326:734-6. doi:10.1126/science.1178258.
3. Treanor J. Influenza vaccine - outmaneuvering antigenic shift and drift. N Engl J Med (2004) 350:218-20. doi:10.1056/NEJMp038238.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 12:36-44. doi:10.1016/S1473-3099(11)70295-X.
5. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol (2009) 333:43-82. doi:10.1007/978-3-540-92165-3_3.
6. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259:1745-9. doi:10.1126/science.8456302.
7. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One (2010) 5:e13162. doi:10.1371/journal.pone.0013162.
8. Macleod MK, David A, Jin N, Noges L, Wang J, Kappler JW, et al. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One (2013) 8:e61775. doi:10.1371/journal.pone.0061775.
9. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med (2010) 16:1389-91. doi:10.1038/nm1210-1389.
10. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 333:850-6. doi:10.1126/science.1205669.
11. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol (2013) 21:350-8. doi:10.1016/j.tim.2013.04.003.
12. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol (2006) 177:2888-98. doi:10.4049/jimmunol.177.5.2888.
13. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 176:6333-9. doi:10.4049/jimmunol.176.10.6333.
14. Lee LY, Ha Do LA, Simmons C, De Jong MD, Chau NV, Schumacher R, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest (2008) 118:3478-90. doi:10.1172/JCI32460.
15. Altenburg AF, Rimmelzwaan GF, De Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine (2015) 33:500-6. doi:10.1016/j.vaccine.2014.11.054.
16. Kreijtz JH, Bodewes R, Van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine (2007) 25:612-20. doi:10.1016/j.vaccine.2006.08.036.
17. Hua L, Yao S, Pham D, Jiang L, Wright J, Sawant D, et al. Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during influenza virus infection. J Virol (2013) 87:11884-93. doi:10.1128/JVI.01461-13.
18. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol (2012) 86:6792-803. doi:10.1128/JVI.07172-11.
19. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 18:274-80. doi:10.1038/nm.2612.
20. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 33:492-503. doi:10.1016/j.immuni.2010.10.002.
21. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 239:178-96. doi:10.1111/j.1600-065X.2010.00978.x.
22. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther (2012) 22:77-89. doi:10.1089/nat.2012.0340.
23. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol (2000) 165:1228-35. doi:10.4049/jimmunol.165.3.1228.
24. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol (2000) 164:2372-8. doi:10.4049/jimmunol.164.5.2372.
25. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2004) 103:2162-9. doi:10.1182/blood-2003-04-1091.
26. Vogel AJ, Harris S, Marsteller N, Condon SA, Brown DM. Early cytokine dysregulation and viral replication are associated with mortality during lethal influenza infection. Viral Immunol (2014) 27:214-24. doi:10.1089/vim.2013.0095.
27. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol (2007) 178:1030-8. doi:10.4049/jimmunol.178.2.1030.
28. Nonacs R, Humborg C, Tam JP, Steinman RM. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J Exp Med (1992) 176:519-29. doi:10.1084/jem.176.2.519.
29. Legge KL, Braciale TJ. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity (2003) 18:265-77. doi:10.1016/S1074-7613(03)00023-2.
30. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol (2007) 7:543-55. doi:10.1038/nri2103.
31. McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J Exp Med (2008) 205:1635-46. doi:10.1084/jem.20080314.
32. Constabel H, Stankov MV, Hartwig C, Tschernig T, Behrens GM. Impaired lung dendritic cell migration and T cell stimulation induced by immunostimulatory oligonucleotides contribute to reduced allergic airway inflammation. J Immunol (2009) 183:3443-53. doi:10.4049/jimmunol.0804223.
33. Kranzer K, Bauer M, Lipford GB, Heeg K, Wagner H, Lang R. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology (2000) 99:170-8. doi:10.1046/j.1365-2567.2000.00964.x.
34. Lawrence CW, Braciale TJ. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol (2004) 173:1209-18. doi:10.4049/jimmunol.173.2.1209.
35. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol (2013) 191:1250-9. doi:10.4049/jimmunol.1300014.
36. Workman AM, Jacobs AK, Vogel AJ, Condon S, Brown DM. Inflammation enhances IL-2 driven differentiation of cytolytic CD4 T cells. PLoS One (2014) 9:e89010. doi:10.1371/journal.pone.0089010.
37. Budd RC, Cerottini JC, Macdonald HR. Phenotypic identification of memory cytolytic T lymphocytes in a subset of Lyt-2+ cells. J Immunol (1987) 138:1009-13.
38. Strutt TM, McKinstry KK, Kuang Y, Bradley LM, Swain SL. Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors. Proc Natl Acad Sci U S A (2012) 109:E2551-60. doi:10.1073/pnas.1205894109.
39. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol (2000) 12:35-43. doi:10.1016/S0952-7915(99)00048-5.
40. Wu F, Yuan XY, Li J, Chen YH. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine (2009) 27:4320-4. doi:10.1016/j.vaccine.2009.04.075.
41. Jiang T, Zhao H, Li XF, Deng YQ, Liu J, Xu LJ, et al. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res (2011) 89:124-6. doi:10.1016/j.antiviral.2010.11.013.
42. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J (2011) 8:97. doi:10.1186/1743-422X-8-97.
43. Gong M, Zhou J, Yang C, Deng Y, Zhao G, Zhang Y, et al. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate. Vaccine (2012) 30:7498-505. doi:10.1016/j.vaccine.2012.10.054.
44. Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol (2013) 190:6221-9. doi:10.4049/jimmunol.1202654.
45. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol (2000) 1:47-53. doi:10.1038/76907.
46. Perez-Giron JV, Belicha-Villanueva A, Hassan E, Gomez-Medina S, Cruz JL, Ludtke A, et al. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J Immunol (2014) 193:1324-32. doi:10.4049/jimmunol.1400222.
47. Gomes MG, White LJ, Medley GF. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. J Theor Biol (2004) 228:539-49. doi:10.1016/j.jtbi.2004.02.015.
48. Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity (2014) 41:886-97. doi:10.1016/j.immuni.2014.12.007.
49. Jonges M, Liu WM, Van Der Vries E, Jacobi R, Pronk I, Boog C, et al. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J Clin Microbiol (2010) 48:928-40. doi:10.1128/JCM.02045-09.
50. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine (1998) 16:1216-24. doi:10.1016/S0264-410X(98)80122-9.